SCHAUMBURG, Ill., Aug. 31, 2011 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a specialty pharmaceutical company, today announced U.S. FDA approval of its Orphenadrine Citrate Injection, USP, a skeletal muscle relaxant. Sagent's orphenadrine will be offered in 60 mg per 2 mL single-dose, latex-free vials. According to 2011 IMS data, the U.S. injectable market for orphenadrine approximated $4.3 million. As with all products in Sagent's portfolio, orphenadrine features the company's PreventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors. Sagent expects to launch orphenadrine in the third quarter of 2011.
